vs

Side-by-side financial comparison of MEDIFAST INC (MED) and NETSTREIT Corp. (NTST). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $57.1M, roughly 1.3× NETSTREIT Corp.). On growth, NETSTREIT Corp. posted the faster year-over-year revenue change (24.3% vs -36.9%). Over the past eight quarters, NETSTREIT Corp.'s revenue compounded faster (20.1% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

NETSTREIT Corp. is a US-headquartered real estate investment trust (REIT) that specializes in acquiring and operating a diversified portfolio of single-tenant net lease commercial properties. Its asset portfolio covers retail, industrial and office categories, primarily catering to investment-grade corporate tenants across the United States market.

MED vs NTST — Head-to-Head

Bigger by revenue
MED
MED
1.3× larger
MED
$75.1M
$57.1M
NTST
Growing faster (revenue YoY)
NTST
NTST
+61.2% gap
NTST
24.3%
-36.9%
MED
Faster 2-yr revenue CAGR
NTST
NTST
Annualised
NTST
20.1%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MED
MED
NTST
NTST
Revenue
$75.1M
$57.1M
Net Profit
$5.7M
Gross Margin
69.4%
Operating Margin
-10.4%
34.1%
Net Margin
10.0%
Revenue YoY
-36.9%
24.3%
Net Profit YoY
235.9%
EPS (diluted)
$-1.64
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
NTST
NTST
Q1 26
$57.1M
Q4 25
$75.1M
$52.5M
Q3 25
$89.4M
$48.3M
Q2 25
$105.6M
$48.3M
Q1 25
$115.7M
$45.9M
Q4 24
$119.0M
$44.1M
Q3 24
$140.2M
$41.4M
Q2 24
$168.6M
$39.6M
Net Profit
MED
MED
NTST
NTST
Q1 26
$5.7M
Q4 25
$1.3M
Q3 25
$-2.3M
$618.0K
Q2 25
$2.5M
$3.3M
Q1 25
$-772.0K
$1.7M
Q4 24
$-5.4M
Q3 24
$1.1M
$-5.3M
Q2 24
$-8.2M
$-2.3M
Gross Margin
MED
MED
NTST
NTST
Q1 26
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Operating Margin
MED
MED
NTST
NTST
Q1 26
34.1%
Q4 25
-10.4%
2.6%
Q3 25
-4.6%
1.3%
Q2 25
-1.0%
6.8%
Q1 25
-1.1%
3.7%
Q4 24
0.6%
-12.3%
Q3 24
1.5%
-12.8%
Q2 24
-4.7%
-5.8%
Net Margin
MED
MED
NTST
NTST
Q1 26
10.0%
Q4 25
2.5%
Q3 25
-2.5%
1.3%
Q2 25
2.3%
6.8%
Q1 25
-0.7%
3.7%
Q4 24
-12.3%
Q3 24
0.8%
-12.8%
Q2 24
-4.8%
-5.8%
EPS (diluted)
MED
MED
NTST
NTST
Q1 26
$0.32
Q4 25
$-1.64
$0.01
Q3 25
$-0.21
$0.01
Q2 25
$0.22
$0.04
Q1 25
$-0.07
$0.02
Q4 24
$0.08
$-0.07
Q3 24
$0.10
$-0.07
Q2 24
$-0.75
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
NTST
NTST
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$1.5B
Total Assets
$248.0M
$2.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
NTST
NTST
Q1 26
Q4 25
$167.3M
Q3 25
$173.5M
Q2 25
$162.7M
Q1 25
$164.6M
Q4 24
$162.3M
Q3 24
$170.0M
Q2 24
$163.5M
Total Debt
MED
MED
NTST
NTST
Q1 26
Q4 25
$1.1B
Q3 25
$1.1B
Q2 25
$926.6M
Q1 25
$913.3M
Q4 24
$868.3M
Q3 24
$778.7M
Q2 24
$726.2M
Stockholders' Equity
MED
MED
NTST
NTST
Q1 26
$1.5B
Q4 25
$198.9M
$1.4B
Q3 25
$214.7M
$1.3B
Q2 25
$216.0M
$1.3B
Q1 25
$211.0M
$1.3B
Q4 24
$210.1M
$1.3B
Q3 24
$207.3M
$1.3B
Q2 24
$205.3M
$1.3B
Total Assets
MED
MED
NTST
NTST
Q1 26
$2.8B
Q4 25
$248.0M
$2.6B
Q3 25
$268.2M
$2.5B
Q2 25
$269.3M
$2.3B
Q1 25
$280.0M
$2.3B
Q4 24
$284.2M
$2.3B
Q3 24
$291.2M
$2.2B
Q2 24
$293.5M
$2.1B
Debt / Equity
MED
MED
NTST
NTST
Q1 26
Q4 25
0.76×
Q3 25
0.84×
Q2 25
0.70×
Q1 25
0.70×
Q4 24
0.65×
Q3 24
0.58×
Q2 24
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
NTST
NTST
Operating Cash FlowLast quarter
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
NTST
NTST
Q1 26
Q4 25
$-5.3M
$109.5M
Q3 25
$12.1M
$28.0M
Q2 25
$-3.4M
$30.6M
Q1 25
$3.4M
$22.1M
Q4 24
$-4.9M
$90.2M
Q3 24
$9.1M
$25.1M
Q2 24
$13.1M
$25.4M
Free Cash Flow
MED
MED
NTST
NTST
Q1 26
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
FCF Margin
MED
MED
NTST
NTST
Q1 26
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Capex Intensity
MED
MED
NTST
NTST
Q1 26
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Cash Conversion
MED
MED
NTST
NTST
Q1 26
Q4 25
82.46×
Q3 25
45.27×
Q2 25
-1.36×
9.36×
Q1 25
13.06×
Q4 24
Q3 24
8.04×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

NTST
NTST

Rental revenue (including reimbursable)$54.0M95%
Other$3.0M5%

Related Comparisons